TITLE

Erratum

PUB. DATE
June 2011
SOURCE
Diabetes Care;Jun2011, Vol. 34 Issue 6, p1442
SOURCE TYPE
Academic Journal
DOC. TYPE
Correction notice
ABSTRACT
A correction to the article "Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes," by R. A. DeFronzo, published in a 2011 issue is presented.
ACCESSION #
65099024

 

Related Articles

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Neurology Alert;Jun2011 Clinical Brief, p12 

    The article presents a report by R. A. DeFronzon published in the "Diabetes Care" journal that informed that Bromocriptine is a new and novel treatment for type 2 diabetes (DM2).

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Infectious Disease Alert;Jun2011 Clinical Briefs in Primary, p12 

    The article discusses research by R. A. DeFronzo on the efficiency of bromocriptine for the treatment of type 2 diabetes, published in a 2011 issue of "Diabetes Care."

  • Bromocriptine for Type 2 Diabetes.  // OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12 

    The article provides a discussion about bromocriptine (BRO) as a novel treatment for type 2 diabetes (DM2) in which it will reset the levels of dopaminergic and sympathetic tone within the central nervous system (CNS).

  • Bromocriptine Mesylate Tablets (Cycloset). Elliott, William T.; Chan, James // Internal Medicine Alert;7/29/2009, Vol. 31 Issue 14, p110 

    The article provides an overview on the efficiency of bromocriptine in treating type 2 diabetes mellitus.

  • Bromocriptine. Pijl, Hanno; Ohashi, Shinichiro; Matsuda, Masafumi; Miyazaki, Yoshinori; Mahankali, Archana; Kumar, Vineeta; Pipek, Ruben; Iozzo, Patricia; Lancaster, Jack L.; Cincotta, Anthony H.; Defronzo, Ralph A. // Diabetes Care;Aug2000, Vol. 23 Issue 8, p1154 

    Focuses on a study which investigated the effect of a quick-release bromocriptine formulation on glucose homeostasis and insulin sensitivity in obese type 2 diabetic subjects. Information on type 2 diabetes; Research design and methods; Conclusions.

  • Pharmacological Management of Type 2 Diabetes Mellitus: An Update. El-Kaissi, Samer; Sherbeeni, Suphia // Current Diabetes Reviews;Nov2011, Vol. 7 Issue 6, p392 

    While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase...

  • Dopamine: The Forgotten Felon in Type 2 Diabetes. Kalra, Sanjay; Kalra, Bharti; Agrawal, Navneet; Kumar, Satish // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jan2011, Vol. 5 Issue 1, p61 

    This paper reviews recent patents and development related to bromocriptine and other dopaminergic agents, being used or suggested for use in the management of diabetes. The article discusses the contribution of dopaminergic pathways to glucose, energy and weight homeostasis. The mechanism of...

  • Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats. Nade, Vandana S.; Kawale, Laxman A.; Todmal, Umesh B.; Tajanpure, Anjali B. // Indian Journal of Pharmacology;Dec2012, Vol. 44 Issue 6, p688 

    Objective: The objective of the present study was to evaluate the effect of bromocriptine on cardiovascular complications associated with type-2 diabetes mellitus (DM). Materials and Methods: Metabolic syndrome or type 2 DM was induced by administration of fructose (66% solution, p.o.) in rats....

  • New formulation of bromocriptine for diabetes. Taylor, James R. // Endocrine Today;Apr2011, Vol. 9 Issue 4, p33 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of quick-release bromocriptine as a new formulation for the treatment of type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics